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VIRAL CAUSES OF GASTROENTERITIS IN THE ERA OF WIDESPREAD
ROTAVIRUS VACCINATIONS. Dame Idossa, Novagrami George, and Virginia Pierce
(Sponsored by Marietta Vázquez). Department of Pediatrics, Yale University, School of
Medicine, New Haven, CT.
Background: It is unknown if widespread use of Rotavirus (RV) vaccine will impact the
primary causative agent of viral gastroenteritis (VGE).
Objective: To identify changes in epidemiology of VGE affected by vaccination,
determine factors associated with higher severity of illness, and assess agreeability
between two clinical severity-grading scales; Clark and Vesikari.
Methods: We analyzed fecal samples of children, 6 months-5 years of age, evaluated at
YNHH for VGE. Fecal samples were tested using a real-time PCR assay. Primer and
probe sequences targeted conserved regions of the genome for RV, Norovirus GI/GII,
Adenovirus, Astrovirus, and Sapovirus. Data were analyzed using SPSS.
Results: Of the 268 fecal samples analyzed, 215 (80%) were positive for at least one
viral pathogen. Of those, 133 (62%) had a single viral pathogen identified and 82 (38%)
had multiple pathogens. The frequencies of pathogens were: RV in 132 (61%), Norovirus
GI/GII in 93 (43%), Astrovirus in 32 (15%), Adenovirus in 24 (11%), and Sapovirus in
21 (10%). For subjects <12 months of age the frequency of viral pathogens were: RV 48
(41%), Norovirus GI/GII 41(35%), Astrovirus 12 (10%), Adenovirus 10 (9%), and
Sapovirus 7 (6%). State of being infected by any pathogen, having educated caretakers,
infection with RV, and not being vaccinated for RV were associated with greater severity
of diarrheal illness. In contrast, difference in severity of illness seen with Hispanic
ethnicity, Black race, and coinfection with multiple pathogens was not statistically
significant. Lastly, Clark and Vesikari clinical severity grading scales were shown to
have poor agreeability (k=0.309), which was not improved by modification.
Conclusions: We conclude that in the era of widespread use of RV vaccine, the
epidemiology of VGE may be changing. We’ve identified several factors that may be
associated with higher severity of illness, which may help guide clinicians in improving
care and directing resources. Lastly, we confirm the poor agreeability between the Clark
and Vesikari scales, which may guide future researchers to standardize use of clinical
severity scales.
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1
INTRODUCTION
Diarrheal illnesses are one of the most common causes of morbidity and mortality in
children worldwide. Acute diarrhea accounts for 2 to 3 million deaths per year with most
occurring in young children in developing countries [1]. Each year in the United States,
gastroenteritis is responsible for approximately 600,000 outpatient medical visits, 55 to
70,000 hospitalizations, and 20 to 60 deaths [2, 3]. The costs associated with diarrheal
illnesses are also very high with total annual direct and indirect costs of approximately $1
billion [4-6]. Below we review the literature on the epidemiology, risk factors, and
clinical severity grading scales for gastroenteritis, with particular attention to viral
gastroenteritis.

Type of Pathogens Causing Gastroenteritis: Parasitic, Bacterial and Viral
The causes of acute diarrhea in children vary depending on multiple factors such as
location, season, and population studied. The infections responsible for causing
gastroenteritis in children can be divided into parasitic, bacterial, and viral infections.

Parasitic causes of diarrhea are not as common in developed countries as they are in the
developing world, however, they still account for 1% to 8% of cases of diarrhea in
pediatric patients. In the United States, Giardia and Cryptosporidium infections are the
most common parasitic causes of disease [7]. They are usually acquired via fecal to oral
transmission. Most community-wide epidemics have resulted from a contaminated water
supply. Person to person transmission can also occur, most commonly in daycare centers.
Prognosis tends to be very good with proper management of disease.
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Bacterial pathogens are the second most common cause of gastroenteritis in pediatric
patients in developed countries, accounting for 2% to 10% of cases [7]. The most
common species include Salmonella, Shigella, and Campylobacter. Other notable
bacteria also includes enterohemorrhagic Escherichia coli (EHEC) and with the
increasing use of antibiotics, Clostridium difficile, although this tends to be uncommon in
the pediatric population [7]. With proper management, the prognosis for bacterial
gastroenteritis tends to be very good, especially in developed countries. Mortality is
usually due to dehydration and malnutrition from a protracted course.

Viral pathogens are by far the most common cause of diarrheal illnesses in the United
States, accounting for 75-90% of pediatric gastroenteritis [8]. Before initiation of the RV
vaccination program in 2006, nearly every child in the United States was infected with
RV by age 5 years; the majority had gastroenteritis, resulting in significant morbidity and
mortality [2]. Other viruses also known to cause gastroenteritis include Norovirus,
Adenovirus, Astrovirus, and Sapovirus. Transmission for all of these viruses is presumed
to be fecal to oral. The morbidity and mortality associated with viral gastroenteritis has
significantly decreased since the initiation of RV vaccination program. The effectiveness
of the RV vaccine is consistent with clinical trials estimates [9]. Studies from the United
States, Europe, and Australia have demonstrated effectiveness of up to 100% (95% CI
85%-100%) associated with decreased hospitalizations for RV gastroenteritis. Healthcare
utilization (hospitalizations and emergency-department visits) was also reduced by up to
90% [10, 11]. Although the efficacy of RV vaccine is reduced in developing countries,
there are still significant reductions in burden of VGE infections. In studies conducted in
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Latin America, RV vaccine has resulted in a 17–51% reduction in gastroenteritisassociated hospitalizations and 59–81% reduction in RV hospitalization among children
younger than five years of age [12].

Characteristics of Viral Agents
Below we review characteristics of the following viruses that were examined in this
study: Rotavirus (RV), Norovirus, Sapovirus, Adenoirus, and Astrovirus.

RV is a double-stranded RNA virus, in the family of Reoviridae, which is classified into
various groups, subgroups, and serotypes. There are at least 15 different serotypes of RV;
presently, 5 serotypes of RV (G1, G2, G3, G4, and G9) account for the majority of the
strains circulating worldwide. Surface antigens VP7 (G protein) and VP4 (P protein) are
2 important structural viral proteins involved in eliciting the immune response through
neutralizing antibodies. Rotaviruses have substantial diversity, with a possible 132
separate G-P combinations [3]. This great diversity of serotypes and surface antigens
creates an opportunity for multiple assortment and combination of RV serotypes,
allowing for the potential emergence of new serotypes of the virus.

Caliciviruses are a family of single-stranded, nonenveloped RNA viruses. The two
recognized genera that cause diarrheal disease in humans are noroviruses (Norwalk-like
viruses) and sapoviruses (Sapporo-like viruses). Sapoviruses have the typical calicivirus
morphology that on electron microscopy reveals the “Star of David” appearance, similar
to many animal caliciviruses. The surface structure of Noroviruses is smooth and
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normally does not reveal the “Star of David” appearance. Noroviruses are known as
“small round structured viruses” [13]. Both Noroviruses and Sapoviruses are genetically
diverse, and multiple strains with distinct genetic identities circulate within a community
at the same time. In the Norovirus genus, the GII strains have been found to be more
common than the GI strains worldwide [14, 15].

Human adenoviruses (HAdVs) are classified in the family Adenoviridae, genus
Mastadenovirus, which contains seven known species, from A to G [16]. They are
double-stranded, linear, nonenveloped DNA viruses. To date there are over 60 distinct
serotypes known to cause human infections. Adenoviruses are known to cause many
types of illnesses including respiratory, ocular, and urinary tract infection [17]. The most
common serotypes that are associated with gastroenteritis are 40, 41, and, to a lesser
extent, 31 [7].

Astrovirus is a nonenveloped, single-stranded RNA viruses with a characteristic starlike
appearance by electron microscopy. Eight human antigenic types are currently known.
Astroviruses have a worldwide distribution and multiple antigenic types are known to cocirculate in the same region [18].

Introduction of Rotavirus Vaccine Program
In 1998, RotaShieldR, a rhesus RV tetravalent vaccine became the first RV vaccine to be
licensed in the United States. Unfortunately, it was recalled shortly after its licensure due
to a rare side effect of intussusception among those vaccinated, resulting in a major set
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back for RV vaccination program [3]. After several years, two different vaccines were
developed, licensed, and approved for use by the US Food and Drug Administration.
RotateqR (RV5) is a pentavalent human-bovine reassortant live-attenuated oral vaccine
licensed in 2006; and RotarixR (RV1) is a monovalent live-attenuated human strain
vaccine, licensed in 2008, which shares neutralizing epitopes against the most common
RV serotypes. Universal RV vaccination was recommended for U.S. infants by the
Advisory Committee on Immunization Practices (ACIP) in February of 2006. 3 doses of
the pentavalent RV vaccine [RV5], RotaTeqR (Merck and Company) were to be given at
ages 2, 4, and 6 months [2, 3]. Since the initiation of this widespread RV vaccination, the
number RV cases and its complications in the United States have been significantly
reduced[19, 20]. Studies from middle and low income countries have also seen many
improvements, including reduction of VGE associated mortality of 22-41% [12].

Clinical Severity Grading Systems
The Vesikari and Clark clinical severity scales were developed and routinely used to
assess severity of cases and assist in investigations of diarrhea and dehydration in RV
vaccine clinical trials.

The Vesikari clinical severity grading system (VSS) is a 20-point scale that is classified
into two categories (non-severe and severe) [21]. Scores greater than or equal to 11 are
considered severe [22]. The Clark clinical severity grading system (CSS) is a 24-point
scale that is classified into three categories (mild, moderate and severe) [23]. Scores less
than 9 are considered mild, scores between 9 and 16 moderate, and scores above 16
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points severe [22]. Both severity scales assess clinical information, such as the magnitude
and duration (in days) of diarrhea and vomiting, and the maximum temperature during
illness. In addition to these parameters, the Clark scale assesses the magnitude and
duration of behavioral symptoms such as irritability and lethargy, and the duration of a
temperature greater than 38.0°C, whereas the Vesikari scale assesses dehydration and
treatment (rehydration or hospitalization) [22].

Several studies have concluded that the Clark scale is less likely to identify a disease as
severe, compared with the Vesikari Clinical Severity Scoring System [24]. Thus it tends
to have a less sensitive measure of severity of illness. This is because among the five
common items included in both scoring systems (# of stools/day, duration of diarrhea, #
of emesis/day, duration of emesis, rectal temperature), the Vesikari scale provided a
higher score for each item compared to the Clark scale, with the exception of temperature
[25]. Thus higher value is reached with a lower frequency of episodes or number of days
of duration with the Vesikari scale, resulting in greater proportion of cases being
classified as “severe”.

7
STATEMENT OF PURPOSE
Since the initiation of the RV vaccine program in 2006, cases of severe gastroenteritis
have significantly decreased [2]. Nevertheless, diarrheal illness and complication
associated with them still account for thousands of outpatient/ED visits and
hospitalization [8]. The current distribution pattern of viral pathogens causing pediatric
gastroenteritis in era of widespread RV vaccination program still remains unknown. Is
the RV still the most common cause or have other viral pathogens, such as astrovirus or
norovirus taken its place?

Understanding the current pathogenic distribution of viral pathogens is of great
importance to improving care for infants and children who suffer from diarrheal illness.
There have been many studies that explore the viral causes of gastroenteritis, both in
developed and developing countries [1, 13-16, 26-28]. There have also been several
studies of active surveillance of certain viruses such as RV, post vaccination program [3,
11, 29]. However, there haven’t been many studies that explore the epidemiology of viral
pathogens known to cause gastroenteritis in the era of wide spread RV vaccination. This
study will seek to identify any changes, if any, in the distributive pattern of viral
gastroenteritis, since the initiation of widespread use of the RV vaccine.

Specific Aim 1: To identify any changes in the epidemiology of viral gastroenteritis.
Hypothesis #1: We predict that RV will still be responsible for causing viral
gastroenteritis in notable portion of children <5 years of age. However, we predict it will
no longer be the most common cause of viral gastroenteritis in children <5 years of age.
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Other viral pathogens, notably Norovirus, will likely take its place.

Specific Aim 2: To determine factors associated with higher severity of illness as graded
by Clark and Vesikari Clinical Severity Scales.
Hypothesis #2: We predict that having infected status, Hispanic ethnicity, Black race,
lower education status of carers of child, infection with RV, no vaccination for RV, and
infection with multiple pathogens will be associated with greater severity of illness.

Specific Aim 3: To determine the agreeability between the clinical severity grading
systems in children seen at Yale New Haven Hospital (Emergency department and
inpatient units).
Hypothesis #3: We predict that there will be poor agreeability between the Clark and
Vesikari clinical severity grading systems.
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MATERIALS AND METHODS
Participants Selection Process
Eligible children were prospectively enrolled into match-controlled study of RV vaccine
effectiveness in children (6 months – 5 years of age) at Yale-New Haven Children’s
Hospital in New Haven, Connecticut January 2010 through June 2011. Eligible children
were those who met all the following criteria:
1) Presented to the hospital with acute gastroenteritis (≥3 looser-than-normal stools
in a 24 –hour period during the illness, and onset of diarrhea ≤ 10 days at
presentation).
2) Diarrhea as the main or one of the main reasons for the visit and managed as an
emergency department (ED) patient or inpatient.
3) Eligible to have received at least one RV1 or RV5 dose ≥14 days before
presentation.
4) Lived in the usual catchment area of the hospital.

Children with immunocompromising condition such as a malignancy or HIV infection
were not eligible, because this made them ineligible from receiving the RV vaccines.
After informed consent was obtained, a standardized questionnaire was administered to
the parent/guardian (which queried demographics, symptoms, name and location of all
immunization providers, and general household information) and a stool sample was
collected. Children were classified as either a RV case or a “RV-negative” gastroenteritis
control based on the RV antigen enzyme immunoassay result. The study was in
collaboration with researchers at the CDC.
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Subjects were interviewed to collect clinical and demographic information. Medical
records were reviewed to assess previous vaccination with RV vaccine and to assess
clinical severity of disease using both the Clark and Vesikari clinical severity scales.
Enrollment was performed approximately 40 hours per week and included evening and
weekend periods. The project was approved by the institutional review boards the
hospital and reviewed for human subjects protection at CDC.

Study Design
We conducted a retrospective cohort study using leftover frozen stool samples from a
previous study that were sent to Children’s Hospital of Philadelphia (CHOP) to be tested
for the presence of viral stool pathogen known to cause VGE such as RV, Adenovirus,
Astrovirus, Sapovirus, and Norovirus using a new real-time PCR assay, developed by the
collaborators at CHOP.

Procedure
A total of 293 frozen specimens [stool samples or diaper lining soaked in viral transport
medium (VTM)] from pediatric patients were tested. All samples had been previously
characterized as either positive (n = 93) or negative (n = 200) for RV by RV-specific
enzyme immunoassay, conducted as part of the case-control investigation by the CDC.
Each stool specimen (both RV positive and negative specimens) was rapidly thawed in a
37oC water bath and then prepared as a 5% suspension in 1.0 ml of nuclease free water,
vigorously vortexed for 30 sec, and clarified by centrifugation at maximum speed for 5
min in a microcentrifuge.
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Real-time PCR Assays
Nucleic acids were extracted from 200 µl of each clinical specimen (prepared 5% stool
suspension supernatant or VTM-soaked diaper lining) by standard procedures using the
MagNA Pure LC automated instrument (Roche Diagnostics, Indianapolis, IN) and
corresponding Roche total nucleic acid isolation kit. Extracted product was heated to
95oC for 5 min and then immediately placed in ice for 1 min. Individual real-time PCR
assays were performed in 50-µl volumes on a 7500 real-time PCR system (Applied
Biosystems, Foster City, CA) using 5 µl of eluted nucleic acid; universal master mixes
for either RNA (Ambion AgPath-ID One-Step RT-PCR master mix; Applied Biosystems)
or DNA (TaqMan universal master mix; Applied Biosystems); universal amplification
conditions consisting of 1 cycle for 10 min at 45°C and 1 cycle for 10 min at 95°C,
followed by 45 two-step cycles of 15 s at 95°C and 45 s at 45°C; and TaqMan
fluorogenic chemistry for detection. Positive and negative controls were processed with
each batch of clinical specimens from extraction of nucleic acids through the detection of
amplified products. Negative controls consisted of 1.0 x 106 cells/ml of an uninfected
human lung carcinoma cell line (A549 cells; ATCC CCL-185), and positive controls
were prepared as a mixture of clinical material from previously positive patients. Notemplate controls were included in each reaction plate for all sets of primers and probes.
Primer and probe sequences targeted conserved regions of the genome for each virus
(Table 1) and were based on the published literature for Adenovirus types 40 and 41[30],
Astrovirus [31], Norovirus genogroups I and II [32], RV [30], and Sapovirus [33].
Specimens and controls were considered positive when the generated fluorescence signal
at the threshold cycle (CT) exceeded a defined threshold limit. Specimens that reached
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the threshold before 38 cycles were considered positive without further testing, and those
that reached the threshold at or after 38 cycles but before the last of 45 cycles were
considered positive only if, upon duplicate repeat testing of separate aliquots of stored
original specimen, at least one of the two repeat tests also reached the threshold before 45
cycles.
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Table 1. Nucleotide sequences of real-time PCR primers and probesa
Primers and
Nucleotide sequences (5’-3’)
probes
Adenovirus 40 and 41
Forward

TTC CAG CAT AAT AAC TCW GGC TTT G

Reverse

AAT TTT TTC TGW GTC AGG CTT GG

Probe

b

Gene target

Hexon

(FAM)-CCW TAC CCC CTT ATT GG-(MGBNFQ)

Astrovirus
Forward

CCD GCC AGR CTC ACA GAA GAG

Reverse

GAC TTG CTA GCC ATC ACA CTY C

Probe

c

(FAM)-ACT CCA TCG-(ZEN)-CAT TTG GAG GGG AGG
ACC-(IABkFQ)
Norovirus genogroups I and II
Genogroup I
forward
Genogroup I
reverse
Genogroup I probe
A
Genogroup I probe
B
Genogroup II
forward
Genogroup II
reverse
Genogroup II probe

Capsid protein
precursor

CGY TCC ATG CGN TTY CAT GA
CTT AGA CGC CAT CAT CAT TYA C
(FAM)-AGA TYG CGA TCY CCT GTC CA-(TAMRA)
(FAM)-AGA TCG CGG TCT CCT GTC CA-(TAMRA)

Polymerase/ca
psid junction

CAR GAR BCN ATG TTY AGR TGG ATC AG
TCG ACG CCA TCT TCA TTC ACA
(VIC)-TGG GAG GGC GAT CGC AAT CT-(TAMRA)

Rotavirus
Forward 1

GGA TGT CCT GTA CTC CTT GTC AAA A

Forward 2

GGA GGT TCT GTA CTC ATT GTC AAA AA

Reverse 1

TCC AGT TTG GAA CTC ATT TCC A

Reverse 2

TCC AGT TTG AAA GTC ATT TCC ATT

Probe 1

(FAM)-ATA ATG TGC CTT CGA CAA T-(MGBNFQ)

Probe 2

(FAM)-AAT ATA ATG TAC CTT CAA CAA T-(MGBNFQ)

Inner capsid
protein VP6

Sapovirus

a

Forward 1

GAC CAG GCT CTC GCY ACC TAC

Forward 2

TTG GCC CTC GCC ACC TAC

Reverse

CCC TCC ATY TCA AAC ACT AWT TTG

Probe

(FAM)-TGG TTY ATA GGY GGT AC-(MGBNFQ)

Polymerase/ca
psid junction

Abbreviations: FAM, 6-carboxyfluorsescein; MGBNFQ, minor groove binder/non-fluorescent quencher;
VIC, proprietary formulation, Applied Biosystems; IABkFQ, Iowa Black FQ quencher, proprietary
formulation, Applied Biosystems; TAMRA, 6-carboxytetramethylrhodamine. International Union of
Biochemistry base codes: W = A or T, D = A or G or T, R = A or G, Y = C or T, B = C or G or T, N = A
or C or G or T.
b
Logan et al. used two probes; we used one probe with mixed bases. cWe incorporated an internal ZEN
quencher from Integrated DNA Technologies, Coralville,
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Resolution of Discordant Results
When there was discordance between real-time PCR and enzyme immunoassay result,
the real-time PCR assay was repeated again using the original sample. If the initial realtime PCR result was positive and one or both of the duplicate retests were positive, the
final PCR result was reported as positive. Conversely, if the initial real-time PCR result
was negative and one or both of the duplicate retests were negative, the final PCR result
was reported as negative.
Omissions
Out of the 293 samples, 18 were duplicates (2 samples collected from same subject). In 1
of the 9 subjects with duplicate samples, one sample was collected from a diaper lining
and the other was collected from a whole stool. In another 3 of the 9 subjects, both
samples were collected from a diaper lining, but were collected on different days. There
was 1 subject in which both samples were from a whole stool, but were collected on 2
different days. In these 5 subjects with duplicate samples, the PCR result for the two
samples gave different results. Thus these 10 samples (from 5 subjects with discordant
results) were omitted from the final analysis. The remaining 4 subjects had a PCR results
that were the same for both of their samples. Because they had a total of 8 samples, 4 of
those samples were omitted from the final analysis to insure that each subject’s sample
was only counted once. The 11 Rota only samples were also omitted in order not to skew
the results towards RV. These were samples tested by EIA and known to have only RV.
This left 268 samples (293-10 discordant-4duplicate-11rota only) to be included in the
analysis of the study.
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Analysis
Data were analyzed with SPSS 14.0 software for Windows. Categorical data were
analyzed using the χ2 test. Continuous variables were analyzed using the t-test procedure.
Cohen kappa statistics used to measure the agreement between the two severity scoring
scales by adjusting both scales to have the same number of categories. A P-value of
<0.05 was considered significant.

Statement of Responsibility
This researcher, Dame Idossa, was responsible for creating a database and compiling all
of all the available data into that database. Novagrami George, BS was responsible for
participant screening and recruitment from January through June 2010 and 2011. Virginia
Pierce MD, our collaborator from CHOP conducted the real-time PCR for all of the
samples and detailed out the methods that were used to do this. This researcher
performed the statistical analysis for all of the data. Dame Idossa, Novagrami George, BS
and Marietta Vázquez, MD interpreted the results.
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RESULTS
Participants
Table 2 presents an overview of the social, demographic, insurance status, parental
education, prematurity, and vaccination status of the 268 analyzed subjects. Overall,
participants were approximately 18 months of age at intake (M=18.12, SD 12.2) and
predominately comprised of males (61.2%). Almost half of the participants (47%)
TABLE 2. Characteristics for N=268 Subjects
Characteristics
Age at Intake (months)
Mean (SD)
Median
Gender
Male
Female
Ethnicity
Hispanic/Latino
Non Hispanic/Latino
Race
White
Black
American Indian
Asian
Other
Insurance
Private
Public
None
Parental education level
<High school
High school/GED
College
Graduate
Prematurity
Full term
Premature
Vaccinations
Rota
Tdap + other vax
Unknown
Clinical Severity score
Mean Clark Clinical Severity scale
Mean Vesikari Clinical Severity scale

Total Cases
N= 268 (%)
18.12 (12.2)
16

Infected
N=215 (%)
18.03 (11.9)
16

Not Infected
N=53 (%)
15.72 (12.6)
13

164 (61.2%
104 (38.8%)

137 (63.7%)
78 (36.3%)

27 (50.1%)
26 (49.1%)

127 (47.4%)
141 (52.6%)

99 (46.0%)
116 (54.0%)

28 (52.8%)
25 (47.2%)

114 (42.5%)
57 (21.3%)
3 (1.1%)
8 (3.0%)
84 (31.3%)

94 (43.7%)
44 (20.5%)
3 (1.40%)
4 1.86%)
67 (31.2%)

20 (37.7%)
13 (24.5%)
0 (0%)
4 (7.5%)
17 (32.1%)

78 (29.1%)
182 (67.9%)
8 (3.0%)

70 (32.6%)
138 (64.2%)
7 (3.26%)

8 (15.1%)
44 (84.9%)
1 (1.9%)

67 (25%)
123 (45.9%)
50 (18.7%)
28 (10.4%)

51 (23.7%)
96 (44.7%)
44 (20.5%)
24 (11.2%)

16 (30.2%)
27 (50.1%)
6 (11.3%)
4 (7.5%)

233 (86.9%)
35 (13.1%)

187 (87.0%)
28 (13.0%)

46 (86.8%)
7 (13.2%)

195 (72.8%)
266 (99.2%)
2 (.75%)

148 (68.8%)
213 (99.1%)
2 (.93%)

47 (88.7%)
53 (100%)
0

10.90 ± 3.4
10.38 ± 3.6

11.13 ± 3.4
10.65 ± 3.6

10.09 ± 3.4
9.24 ± 3.7
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identified as Hispanic/Latino ethnicity. 42.5% of the participants identified as Caucasian,
with the rest identifying as Black (21.3%), American Indian (1.1%), Asian (3.0%), and
other (31.3%). The majority of the participants had health insurance coverage through
public (67.9%) or private (29.1%) institutions. A quarter of the parents of participants had
less than a high school level of education with the rest having high school diploma/GED
(45.9%), College degree (18.7%) or Graduate degree (10.4%). Most of the children were
born at full term (86.9%) and had received RV vaccine (72.8%) and other childhood
vaccines (99.2%). The mean clinical severity score as determined by the Clark scale was
10.9 ± 3.4 and by Vesikari scale was 10.38 ± 3.6. The stratified characteristics for the
participants infected with any pathogen and for those not infected with any tested
pathogen were also similar and as listed in Table 2.
Pathogens and Severity
Tables 3, 4, and 5 describe the pathogens detected in subjects who were infected. Of the
215 infected subjects, 133 (49.5%) were single infections and 82 (30.6%) were multiple
infections. Overall, Adenovirus was detected in 24 (11.2%), Astrovirus in 32 (14.9%),
Norovirus GI in 4 (1.9%), Norovirus GII in 89 (41.4%), RV in 132 (61.4%), and
Sapovirus in 21 (9.8%) of the participants.

Of the 215 infected participants, RV caused the greatest severity of illness as measured
by the Clark Clinical Severity scale 11.7 ± 3.4, followed by Adenovirus, Norovirus GII,
Astrovirus, Sapovirus, and Norovirus GI (Table 3). However, Adenovirus caused the
greatest severity of illness as measured by the Vesikari Clinical Severity scale 12 ± 3.4,
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followed by RV, Norovirus GII, Astrovirus, sapovirus, and lastly Norovirus GI, as shown
in Table 3.
TABLE 3. Pathogens Detected in Infected subjects
Pathogens Detected
Total Cases
N= 215 (%)
Adenovirus
24 (11.2)
Astrovirus
32 (14.9)
Norovirus GI
4 (1.9)
Norovirus GII
89 (41.4)
Rotavirus
132 (61.4)
Sapovirus
21 (9.8)

Mean Clark
Scale (SD)
11.5 (3.1)
10.2 (3.2)
8.8 (4.5)
10.9 (3.3)
11.7 (3.4)
9.5 (2.7)

Mean Vesikari
Scale (SD)
12 (3.4)
9.44 (3.9)
7.25 (3.6)
10.66 (3.4)
11 (3.6)
9.19 (3.4)

* Total adds up to > 215 because 82 subjects were coinfected with multiple pathogens and hence counted >1 times
Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe”

Single Viral Infections
Of the 133 subjects infected with a single virus, 8 (6%) were infected by Adenovirus, 8
(6%) by Astrovirus, 42 (32%) by Norovirus GII, 66 (50%) by RV, and 9 (7%) by
Sapovirus. In these subjects, Adenovirus caused the greatest severity of illness as
measured by the Clark Clinical Severity scale 12.1 ± 3.7, followed by RV, Norovirus GII,
Astrovirus, and Sapovirus (Table 4). However, RV caused the greatest severity of illness
as measured by the Vesikari Clinical Severity scale 12.5 ± 3.3, followed by Adenovirus,
Norovirus GII, Astrovirus, Sapovirus, as shown in Table 4.
TABLE 4. Pathogens Detected in Single Infections
Pathogens Detected
Total Cases
N= 133 (%)
Adenovirus
8(6)
Astrovirus
8(6)
Norovirus GI
Norovirus GII
42(32)
Rotavirus
66(50)
Sapovirus
9(7)

Mean Clark
Scale (SD)
12.1 (3.7)
8.6 (2.8)
10.1 (3.1)
11.6 (3.6)
8.2 (2.3)

Mean Vesikari
Scale (SD)
10.4 (2.1)
9.6 (2.4)
10.1 (3.3)
12.5 (3.3)
8.6 (3.2)

Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe”
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Multiple Viral Infections
Of the 82 subjects who were co-infected by multiple viruses, 15 (18.3%) were infected by
Adenovirus, 26 (31.7%) by Astrovirus, 4 (4.9%) by Norovirus GI, 49 (59.8%) by
Norovirus GII, 71 (86.6%) by RV, and 12 (14.6%) by Sapovirus. In these subjects,
Adenovirus caused the greatest severity of illness as measured by the Clark Clinical
Severity scale 12.3 ± 3.5, followed by Norovirus GII, RV, Astrovirus, Sapovirus and
Norovirus GI (Table 5). Similarly Adenovirus caused the greatest severity of illness when
measured by the Vesicari Clinical severity score 12.1 ± 3.5, followed by Norovirus GII,
RV, Sapovirus, Astrovirus, and Norovirus GI (Table 5).
TABLE 5. Pathogens Detected in Multiple Infections
Pathogens Detected
Total Cases
N= 133 (%)
Adenovirus
15(18.3)
Astrovirus
26(31.7)
Norovirus GI
4(4.9)
Norovirus GII
49(59.8)
Rotavirus
71(86.6)
Sapovirus
12(14.6)

Mean Clark
Scale (SD)
12.33 (3.5)
10.42 (3.4)
8.75 (5.2)
11.61 (3.3)
11.14 (3.4)
10.17 (2.4)

Mean Vesikari
Scale (SD)
12.13 (3.5)
9.54 (4.2)
7.25 (4.1)
11.24 (3.5)
10.51 (3.5)
9.92 (4.1)

* Total adds up to > 82 because all of these subjects were coinfected with multiple pathogens
Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe”

Pathogens by Age
When we stratified participants by age, the children between 0-12 months of age were
most commonly infected by RV 48 (40.7%), followed by Norovirus GII 40 (33.9%),
Astrovirus 12 (10.2%), Adenovirus 10 (8.5%), Sapovirus 7 (5.9%), and Norovirus GI 1
(0.85%). This trend was similar for children between 12-24 months and 24-36 months.
For children who were ≥ 36 months of age, RV 8 (72.7%) caused the majority of the
infections found. Astrovirus, Norovirus GII, and Sapovirus all caused 1 (9.1%) of the
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infections detected in this age group. Adenovirus and Norovirus GI did not cause any
infections (Table 6).

TABLE 6. Pathogens by Age
Pathogens Detected
Adenovirus
Astrovirus
Norovirus GI
Norovirus GII
Rotavirus
Sapovirus

0-12 mo
N= 118 (%)
10 (8.5)
12 (10.2)
1 (.85)
40 (33.9)
48 (40.7)
7 (5.9)

12-24 mo
N= 122 (%)
9(7.4)
15 (12.3)
0
38 (31.1)
53 (43.4)
7 (5.7)

24-36 mo
N= 57 (%)
4 (7)
6 (10.5)
3 (5.3)
11 (19.3)
47.4)
6 (10.5)

36+ mo
N= 11 (%)
0
1 (9.1)
0
1 (9.1)
8 (72.7)
1 (9.1)

* Total adds up to > 264 because of coinfections

RV Vaccination Status’ Effects on Infection With Pathogens and Severity of Illness
Of the 268 participants, 195 (72.8%) were vaccinated against RV with at least one dose
of RotateqR or RotarixR vaccine. In these participants, RV was the most common viral
pathogen detected 83 (38.4%), followed by Norovirus GII 73 (33.8%), Astrovirus 27
(12.5%), Sapovirus 16 (7.4%), Adenovirus 13 (6.02%), and Norovirus GI 4 (1.85).
Adenovirus had the highest severity of illness when measured using the Clark Clinical
Severity scale 11.5 ± 2.8, followed by RV, Norovirus GII, Astrovirus, Sapovirus, and
Norovirus GI (Table 7). Adenovirus also caused the greatest severity of illness as
measured by the Vesikari Clinical Severity scale 11.9 ± 3.6, followed by Norovirus GII,
RV, Astrovirus, Sapovirus, and Norovirus GI (Table 7).
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TABLE 7. Pathogens Detected in Rotavirus Vaccinated Participants
Pathogens
N=216 (%) Clark Scale
(SD)
Adenovirus
13 (6.0)
11.54 (2.8)
Astrovirus
27 (12.5)
9.82 (3.1)
Norovirus GI
4 (1.9)
8.87 (4.5)
Norovirus GII
73 (33.8)
10.52 (3.2)
Rotavirus
83 (38.4)
10.73 (3.1)
Sapovirus
16 (7.4)
9.56 (2.8)

Vesikari
Scale (SD)
11.92 (3.6)
9.18 (4.2)
7.25 (3.6)
10.52 (3.3)
9.87 (3.2)
9 (3.6)

* Total adds up to > 195 because of coinfections
Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe”

Of the 73 (27.2 %) participants who were not vaccinated with at least one dose of
RotateqR or RotarixR vaccine, RV was the most common viral pathogen detected 48
(58.5%), followed by Norovirus GII 15 (18.3%), Adenovirus 11 (13.4%), Astrovirus and
Sapovirus both detected in 4 (4.9%) of the stool samples. Norovirus GI did not cause any
infections in these participants. RV caused the greatest severity of illness as measured by
the Clark Clinical Severity scale 13.4 ± 3.0, followed by Astrovirus, Norovirus GII,
Adenovirus, and Sapovirus (Table 8). Conversely, Astrovirus caused the greatest severity
of illness as measured by the Vesikari Clinical Severity scale 13.3 ± 2.1, followed by RV,
Adenovirus, Norovirus GII, and Sapovirus (Table 8).
TABLE 8. Pathogens Detected Rotavirus Non Vaccinated Participants
Pathogens
N=82 (%)
Clark Scale
(SD)
Adenovirus
11 (13.4)
11.45 (3.5)
Astrovirus
4 (4.9)
13.25 (2.5)
Norovirus GI
0
Na
Norovirus GII
15 (18.3)
12.67 (3.6)
Rotavirus
48 (58.5)
13.44 (3.0)
Sapovirus
4 (4.9)
9.75 (2.4)

Vesikari Scale
(SD)
12.09 (3.1)
13.25 (2.1)
Na
11.33 (3.8)
12.98 (3.3)
10.75 (2.3)

* Total adds up to > 73 because of coinfections
Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe”
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Factors Associated with Higher Severity of Illness
We explored various factors that may be associated with higher severity of illness using
T-test. Both the Clark and Vesikari severity scales were used to measure severity. Table 9
depicts the p values of the various characteristics tested.

State of being infected by any pathogen, having educated caretakers (some college or
greater level of education), infection with RV, and not being vaccinated for RV were
associated with greater severity of illness. In contrast, having multiple infections, being
of Hispanic ethnicity and being of Black race were not associated with greater severity of
illness (Table 9).
Table 9. Factors association with Severity of Illness
Characteristics
Mean CSS
P-value
CSS
Non Vaccinated vs Vaccinated 12.59 vs 10.31
<0.001
Rotavirus vs non Rotavirus
12.53 vs 9.88
<0.001
Rotavirus vs Norovirus GII
12.53 vs 10.00
<0.001
Rotavirus vs Sapovirus
12.53 vs 8.55
0.001
Rotavirus vs Astrovirus
12.53 vs 9.63
0.018
≤HS diploma vs >HS diploma 10.75 vs 11.70
0.035
Infected vs non Infected
11.13 vs 10.09
0.047
Rotavirus vs Adenovirus
12.53 vs 10.38
0.076
Black vs non Black race
10.67 vs 11.59
0.100
Public vs Private Insurance
10.85 vs 11.54
0.130
Non Hispanic vs Hispanic
10.71 vs 11.00
0.668
Single vs Multiple Infections
11.14 vs 10.74
0.944

Mean VSS
12.29 vs 9.70
11.64 vs 9.88
11.64 vs 10.00
11.64 vs 8.22
11.64 vs 8.63
9.83 vs 12.05
10.65 vs 9.25
11.64 vs 12.13
10.25 vs 11.34
9.88 vs 11.76
10.65 vs 9.25
11.11 vs 10.55

P-value
VSS
<0.001
0.002
0.013
0.006
0.023
<0.001
0.011
0.718
0.062
<0.001
0.011
0.741

Agreeability Between Vesikari and Clark Severity Scales
Figure 1 shows all cases (N=268) graded by both the Vesikari and Clark severity grading
scales individually (Panels A and B). The Clark Severity Scale was modified into a 2
category scale by grouping the mild and moderate cases into “non severe.” This modified
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Clark scale was then compared to the Vesikari Scale as in shown in panel C. Lastly the
Vesikari scale was modified into a 3-category system by regrouping into mild, moderate,
and severe groups. This modified Vesikari scale was compared the original scale as
shown in panel D.

Figure 1. Agreeability of Clark and Vesikari Severity Grading Scales

A and B show cases as graded by Vesikari and Clark scale respectively. C shows cases as graded by
Vesikari and modified 2-category Clark scale. D shows cases as graded by Clark and modified 3-category
Vesikari scale. Blue=Clark, Red=Vesikari.

The comparison between the two scoring scales cannot be analyzed statistically because
the distribution categories are not even. The Clark scale is divided into 3 ranges (<9, 9–
16 and >16) while the Vesikari scale is divided into 2 ranges only (<11 and ≥11). Thus
we modified Clark scale into a 2-category scale and the Vesikari into a 3-category scale
to make the comparisons. The Cohen’s Kappa coefficient [34] was used to determine the
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agreeability between the Clark and Vesikari severity grading scales. Kappa values can
range from -1 to 1. Values <1 suggest poor agreement, 0-0.20 slight agreement, 0.21-0.40
fair agreement, 0.41-0.60 moderate agreement, 0.61-0.8 substantial agreement, and 0.811 almost perfect agreement. As depicted in Table 10, the Kappa scores for the original
and modified Vesikari and Clark scales show there is slight or fair agreement at best
between the two grading systems.

Table 10. Agreeability between Vesikari and Clark grading systems
Type of scale
Kappa value
95%CI
Original
.306
(0.218,0.394)
Modified Clark
.111
(0.050-0.172
Modified Vesikari
.326
(0.244-0.408)

P-value
<0.001
<0.001
<0.001
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DISCUSSION
RV vaccines have significantly reduced the burden of RV disease both in the United
States and globally. Studies in the United States have shown a decline of approximately
85% to 95% in RV cases during the 2008 season compared with previous seasons [2]. In
addition, data from the Natural Respiratory and Enteric Virus Surveillance System
(NREVSS), network of U.S. laboratories that provide the CDC with weekly reports of the
number of tests performed and positive results obtained for a variety of pathogens, have
shown a >50% decrease of RV positive samples in 2007–2008 season of RV when
compared to the season of 1991–2006 [29]. Studies from developing countries have
shown lower efficacy of the vaccine; nonetheless, great reductions in severe diarrheal
illness in children who received the RV vaccine. For example, studies from Bangladesh
and Vietnam have shown the vaccine to be 48% efficacious against severe disease in
young infants [35, 36]. RV vaccine has undoubtedly reduced the mortality and morbidity
associated with viral gastroenteritis in young children.

There have also been studies that have demonstrated a shift in the seasonality of RV since
initiation of RV vaccine [37]. In addition, the usual spread of RV associated
gastroenteritis from southwest to northeast has not been shown post RV vaccine
initiation. The RV season has also been noted to be later in the year, shorter, and less
pronounced when compared to pre-vaccination era [29]. All of this information suggests
that the morbidity and mortality associated with RV gastroenteritis is increasingly
becoming better managed.
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Interesting results in regards to distribution of pathogens post RV vaccination program
have emerged from our study. Overall, our data shows RV remains the most common
cause of both single and co-infections causing viral gastroenteritis in children in CT.
Given the successes of the RV vaccination program [38], this is unexpected, although not
surprising. There are many different types of the RV serotypes and surface antigens [39].
This great diversity of serotypes and surface antigens creates an opportunity for multiple
assortment and combination of RV serotypes, allowing for the potential emergence of
new serotypes of the virus. The current vaccines available cannot protect against all of
the possible RV serotypes or any new serotypes that emerge.

In subjects who were previously vaccinated for RV, the frequency of RV infection was
significantly decreased, as expected (38%), and we have noted the frequency of
Norovirus GII has increased (34%). The data from those who were not vaccinated for RV
seems to be similar to data from pre RV vaccination era, with RV accounting for nearly
60% of the viral gastroenteritis. In this group Norovirus GII is found to cause only 18%
of disease. An interesting result from this study is the change in the frequency of
Norovirus infections when the data were stratified by ages. Norovirus GII frequency is
increased mostly in the children <12months, who are the target population for RV
vaccination programs. This may suggests this trend may be a direct result of RV being
better controlled in this age group. A recent active surveillance study, since the
introduction of RV vaccines, found that Norovirus has become the leading cause of
medically attended acute gastroenteritis in U.S. children and is associated with nearly 1
million health care visits annually. They estimated treatment cost associated with
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Norovirus is >$270 million and expected to continue rising [40]. Given the recent
advances in the development of candidate Norovirus vaccines [27, 41], the need to
determine the burden of gastroenteritis associated with Norovirus and other viruses is
increasingly more important.

Several factors associated with increased severity of illness emerged from our study.
Primarily, the detection of any viral pathogen tested was associated with greater severity
of illness as expected. Subjects who exhibited symptoms of viral gastroenteritis but did
not shed any of the viruses tested could have been infected with parasitic, bacterial, or
viral agents that were not tested for. Regardless, these subjects had less severe disease
manifestations than their viral infected counterparts. As predicted subjects who were not
vaccinated against RV had a greater severity of illness (P=<0.001) (regardless of what
pathogen they were infected with) when compared to those that were vaccinated against
RV. We also found, higher education of status of caretakers was found to be associated
with higher severity of illness as measured by both Clark (11.70 p=0.035) and Vesikari
((12.05 p=<0.001) Scale. Given the usual association of higher level of education with
higher annual income and, typically, better access to care/better health outcomes, this
result was unexpected. A possible explanation for this could be that caretakers with
higher level of education could potentially have more demanding jobs and presumably
present their child to the ED/hospital at later or more severe stages of disease. This could
result in detection or ascertainment bias. Lastly, subjects who were infected with RV, as
either a single infection of a co-infection, were found to have greater severity of illness as
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expected. Other studies have also shown that RV associated gastroenteritis cause the
greatest severity of illness in children <5 years old [42, 43].

Health disparities in the United States are pervasive and present in almost all realms of
medicine. In primary care, minority children are more likely to receive poorer quality of
care in terms of provider interactions, preventive services and management of common
conditions [44]. However, contrary to our hypothesis, the results of this study did not
support his fact. Hispanic ethnicity did not result in higher severity of illness, in fact nonHispanics were found to have greater severity of illness only by the Vesikari scale
(p=<0.001). The difference in severity measured by the Clark Scale was found to be not
statistically significant (p=0.095). Black race was also not associated with greater
severity of illness, when measured by both the Clark (p=0.100) and Vesikari (p=0.062)
scale. Lastly, subjects with public insurance were also not found to have higher severity
of illness. In fact, subjects with private insurance were found to have a greater severity of
illness as measure only by the Vesikari scale (p=<0.001). The data from this study did not
demonstrate disparities in severity of illness among minority or poor participants.

Interestingly, being infected with more than one pathogen also did not result in greater
severity of illness as predicted. In fact our data demonstrated the difference between
severity of illness of those with single and multiple infections was not statistically
significant when measured by both the Clark (p=0.944) and Vesikari (p=0.741) scale.
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As predicted the Clark and Vesikari severity grading systems had poor agreeability even
with modification of the scales. The results obtained using the two severity scales differ
significantly and can disrupt comparisons [25]. The original scales were found to have
only fair agreement as measured by the kappa score. When the Clark three-category scale
was transformed into a two-category scale by combining mild and moderate categories as
non-severe, the agreeability actually worsened. Modifying the Vesikari two-category
scale into a three-category scale by further subdividing the severe category into two parts,
provided a better correlation between the two severity scales, but still did not achieve a
good level of agreement. This suggests that there either needs to be a development of a
new severity grading system or standardized use of only one of the existing scales in
subsequent research/clinical trials.
Limitations
There are several limitations of this study. The greatest limitation is our choice of
modality for detecting pathogens in the stool samples. The real time PCR assay was
designed to detect sequences of conserved regions of the genome for RV, Norovirus
GI/GII, Adenovirus, Astrovirus, and Sapovirus. Thus other viral pathogens, if present,
would not be detected via this method. However, previous studies support the notion that
the selected viral agents are known to cause the majority of viral gastroenteritis in the
United States and worldwide [30-32, 45, 46] Additionally, the real time PCR does not
detect other causative agents of gastroenteritis such as bacteria or parasitic agents. The
subjects who were exhibiting symptoms of gastroenteritis, but did not show infection by
the tested pathogens likely had infection with bacterial, parasitic, or other viral
pathogens. Secondly, the study analyzed data collected from January-June. There is a
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possibility that some viruses that are seen in the other months were not fully accounted
for in our study. Lastly, there were some samples that were omitted from the study due to
differing PCR results. There are a number of reasons why the PCR results for two
different samples from the same subject might give different results. Primarily, the timing
of sample collection is important. Samples obtained on different days are more likely to
give different results. Secondly, the sample type is also important. Stool vs. diaper lining
squeezed out into viral transport medium (which dilutes the specimen) is more likely to
give different results. In addition, the samples could have had low viral load. One test
might be positive and the other negative in different samples if the PCR target was
present in only very small amounts. Lastly, there is always the possibility of
contamination of the sample and problems with the sample quality/specimen handling.
These are some possible reasons for why we had these samples from the same subject
produce different PCR results.
Clinical implications
Currently, there are no studies that identify the epidemiological changes in the causative
pathogens of VGE in post the widespread RV vaccination programs. Based on results
from our study, we conclude that in the era of widespread use of RV vaccine, the most
common agent causing VGE at YNH children's hospital still remains RV. Norovirus
frequency seems to be increasing, mostly in the younger children who are the target
population for RV vaccination program. This suggests the epidemiology of VGE may
indeed be changing as more children are protected from RV. We’ve identified several
factors that may be associated with higher severity of illness, which may help guide
clinicians in improving care and directing resources. Lastly, we’ve confirmed the poor
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agreeability between the Clark and Vesikari scales, which may guide future researchers
to standardize use of clinical severity scales.
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